propels innovation

Ichnos Glenmark Innovation

Who we are

Ichnos Glenmark Innovation, an alliance between Ichnos Sciences Inc. and Glenmark Pharmaceuticals Limited, combines internal prowess and external potentialities to create cutting-edge therapy solutions.

Solutions that treat hematological malignancies and solid tumors to bring new hope for patients, their families and healthcare professionals alike.

At a Glance

  • Diversity of immune cell engagement and indications across hematologic and solid tumors

  • Proprietary protein engineering platform allowing maximal flexibility and manufacturability of full length multispecific antibodies

  • Discovery engine to sustain innovation and drive long-term growth
  • A highly experienced management team with a combined experience of 144 years

  • Approximately 150+ employees singularly focused on pushing the boundaries of oncology cancer treatment/therapy

  • Scientific Advisory Board with extensive expertise in drug development, immuno-oncology, and protein engineering

3 state-of-the-art centers of innovation in USA, Switzerland and India

  • Company headquarters in New York, USA, focused on clinical  development, general and administration

  • Biologics and early discovery research center at Biopôle, Lausanne in Switzerland

  • Small Molecule Research Center at Mahape in Mumbai, India

Robust pipeline


Robust Pipeline

Latest Updates


30 April 2024